Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1818.53
OMPI's Cash to Debt is ranked lower than
126% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. OMPI: 1818.53 )
Ranked among companies with meaningful Cash to Debt only.
OMPI' s 10-Year Cash to Debt Range
Min: 0.05  Med: 298.08 Max: No Debt
Current: 1818.53
Equity to Asset 0.66
OMPI's Equity to Asset is ranked lower than
179% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OMPI: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
OMPI' s 10-Year Equity to Asset Range
Min: -0.82  Med: 0.62 Max: 0.71
Current: 0.66
-0.82
0.71
Interest Coverage 1959.20
OMPI's Interest Coverage is ranked lower than
281% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMPI: 1959.20 )
Ranked among companies with meaningful Interest Coverage only.
OMPI' s 10-Year Interest Coverage Range
Min: 2  Med: 1053.70 Max: 1000
Current: 1959.2
2
1000
F-Score: 6
Z-Score: 16.58
M-Score: -2.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 22.70
OMPI's Operating margin (%) is ranked lower than
162% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. OMPI: 22.70 )
Ranked among companies with meaningful Operating margin (%) only.
OMPI' s 10-Year Operating margin (%) Range
Min: 7.6  Med: 22.70 Max: 38
Current: 22.7
7.6
38
Net-margin (%) 13.80
OMPI's Net-margin (%) is ranked lower than
162% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. OMPI: 13.80 )
Ranked among companies with meaningful Net-margin (%) only.
OMPI' s 10-Year Net-margin (%) Range
Min: 2.5  Med: 12.90 Max: 25
Current: 13.8
2.5
25
ROE (%) 26.90
OMPI's ROE (%) is ranked lower than
139% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. OMPI: 26.90 )
Ranked among companies with meaningful ROE (%) only.
OMPI' s 10-Year ROE (%) Range
Min: 15.7  Med: 26.90 Max: 252.1
Current: 26.9
15.7
252.1
ROA (%) 20.30
OMPI's ROA (%) is ranked lower than
125% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. OMPI: 20.30 )
Ranked among companies with meaningful ROA (%) only.
OMPI' s 10-Year ROA (%) Range
Min: 3.3  Med: 17.40 Max: 28.9
Current: 20.3
3.3
28.9
ROC (Joel Greenblatt) (%) 153.60
OMPI's ROC (Joel Greenblatt) (%) is ranked lower than
130% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. OMPI: 153.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OMPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 65.9  Med: 103.80 Max: 241.5
Current: 153.6
65.9
241.5
Revenue Growth (3Y)(%) 8.60
OMPI's Revenue Growth (3Y)(%) is ranked lower than
265% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. OMPI: 8.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OMPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -0.2  Med: 5.70 Max: 14.4
Current: 8.6
-0.2
14.4
EBITDA Growth (3Y)(%) 13.70
OMPI's EBITDA Growth (3Y)(%) is ranked lower than
249% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. OMPI: 13.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OMPI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -0.80 Max: 50.5
Current: 13.7
0
50.5
EPS Growth (3Y)(%) 15.00
OMPI's EPS Growth (3Y)(%) is ranked lower than
258% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OMPI: 15.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OMPI' s 10-Year EPS Growth (3Y)(%) Range
Min: -10.6  Med: 2.00 Max: 15
Current: 15
-10.6
15
» OMPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OMPI Guru Trades in

OMPI Guru Trades in

OMPI Guru Trades in

Q2 2013

OMPI Guru Trades in Q2 2013

Mario Gabelli 1,235,584 sh (+12.96%)
First Eagle Investment Sold Out
Chuck Royce Sold Out
Jim Simons Sold Out
Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 13.50
OMPI's P/E(ttm) is ranked lower than
493% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 40.90 vs. OMPI: 13.50 )
Ranked among companies with meaningful P/E(ttm) only.
OMPI' s 10-Year P/E(ttm) Range
Min: 8.45  Med: 21.38 Max: 57.79
Current: 13.5
8.45
57.79
PE(NRI) 13.50
OMPI's PE(NRI) is ranked lower than
497% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 39.90 vs. OMPI: 13.50 )
Ranked among companies with meaningful PE(NRI) only.
OMPI' s 10-Year PE(NRI) Range
Min: 0  Med: 0.00 Max: 0
Current: 13.5
P/B 3.49
OMPI's P/B is ranked lower than
143% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: 4.68 vs. OMPI: 3.49 )
Ranked among companies with meaningful P/B only.
OMPI' s 10-Year P/B Range
Min: 1.45  Med: 3.70 Max: 20.54
Current: 3.49
1.45
20.54
P/S 1.88
OMPI's P/S is ranked lower than
180% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. OMPI: 1.88 )
Ranked among companies with meaningful P/S only.
OMPI' s 10-Year P/S Range
Min: 0.89  Med: 2.10 Max: 5.03
Current: 1.88
0.89
5.03
PFCF 12.78
OMPI's PFCF is ranked lower than
749% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 41.97 vs. OMPI: 12.78 )
Ranked among companies with meaningful PFCF only.
OMPI' s 10-Year PFCF Range
Min: 7.95  Med: 16.40 Max: 38.21
Current: 12.78
7.95
38.21
EV-to-EBIT 13.98
OMPI's EV-to-EBIT is ranked lower than
477% of the 223 Companies
in the Global Biotechnology industry.

( Industry Median: 30.72 vs. OMPI: 13.98 )
Ranked among companies with meaningful EV-to-EBIT only.
OMPI' s 10-Year EV-to-EBIT Range
Min: 4.1  Med: 10.90 Max: 24.5
Current: 13.98
4.1
24.5
PEG 1.34
OMPI's PEG is ranked lower than
1458% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.75 vs. OMPI: 1.34 )
Ranked among companies with meaningful PEG only.
OMPI' s 10-Year PEG Range
Min: 0.68  Med: 1.73 Max: 11.6
Current: 1.34
0.68
11.6
Shiller P/E 18.92
OMPI's Shiller P/E is ranked lower than
985% of the 108 Companies
in the Global Biotechnology industry.

( Industry Median: 48.44 vs. OMPI: 18.92 )
Ranked among companies with meaningful Shiller P/E only.
OMPI' s 10-Year Shiller P/E Range
Min: 16.8  Med: 20.92 Max: 38.52
Current: 18.92
16.8
38.52
Current Ratio 3.91
OMPI's Current Ratio is ranked lower than
131% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. OMPI: 3.91 )
Ranked among companies with meaningful Current Ratio only.
OMPI' s 10-Year Current Ratio Range
Min: 0  Med: 0.00 Max: 0
Current: 3.91
Quick Ratio 4.34
OMPI's Quick Ratio is ranked lower than
131% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OMPI: 4.34 )
Ranked among companies with meaningful Quick Ratio only.
OMPI' s 10-Year Quick Ratio Range
Min: 0  Med: 0.00 Max: 0
Current: 4.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.50
OMPI's Price/Net Cash is ranked lower than
238% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 8.45 vs. OMPI: 0.50 )
Ranked among companies with meaningful Price/Net Cash only.
OMPI' s 10-Year Price/Net Cash Range
Min: 10.4  Med: 19.05 Max: 385
Current: 0.5
10.4
385
Price/Net Current Asset Value 0.40
OMPI's Price/Net Current Asset Value is ranked lower than
200% of the 533 Companies
in the Global Biotechnology industry.

( Industry Median: 7.60 vs. OMPI: 0.40 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OMPI' s 10-Year Price/Net Current Asset Value Range
Min: 7.9  Med: 11.80 Max: 23.2
Current: 0.4
7.9
23.2
Price/Tangible Book 0.10
OMPI's Price/Tangible Book is ranked lower than
156% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. OMPI: 0.10 )
Ranked among companies with meaningful Price/Tangible Book only.
OMPI' s 10-Year Price/Tangible Book Range
Min: 3.3  Med: 4.60 Max: 26.4
Current: 0.1
3.3
26.4
Price/Graham Number 0.10
OMPI's Price/Graham Number is ranked lower than
622% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. OMPI: 0.10 )
Ranked among companies with meaningful Price/Graham Number only.
OMPI' s 10-Year Price/Graham Number Range
Min: 1.4  Med: 2.10 Max: 6
Current: 0.1
1.4
6
Earnings Yield (Greenblatt) (%) 7.20
OMPI's Earnings Yield (Greenblatt) (%) is ranked lower than
130% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. OMPI: 7.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OMPI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 4.1  Med: 9.20 Max: 24.6
Current: 7.2
4.1
24.6
Forward Rate of Return (Yacktman) (%) 7.22
OMPI's Forward Rate of Return (Yacktman) (%) is ranked lower than
1223% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 14.58 vs. OMPI: 7.22 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OMPI' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -8.8  Med: 3.20 Max: 34.3
Current: 7.22
-8.8
34.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:O1P.Germany,

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK